Jul. 29 at 9:54 PM
$CORT $LXRX In the past 20 years, we have seen tremendous market successes of hormonal therapies and medications such as SGLT inhibitors ('gliflozin) and GLP-1 receptor agonists (Semaglutide , Tirzepatide) - both had made hundreds of
$B's for Eli Lilly (Jardiance), AstraZeneca (Farxiga), Novo Nordis (Wegovy ...), Eli Lilly (Zepbound ...).
While the successes of SGLT-inhibitors and GLP-1 agonists continue, we are witnessing another emerging hormonal therary/medication being catapulted into the markets, which is championed by Corcept Therapeutics (CORT). Two approved drugs from CORT for, respectively, Cushing syndrome, and Platinum Resistant Ovarian Cancer (PROC), another one (Relacorilant/CS) under NDA review, at FDA, two in late-stage clinical trial: Dazucorilant/ALS and Miricorilant/MASH, and one in early-state clinical trial: Nenocorilant/solid-tumors.
No question that our bodies' normal functions are build on hormonal balances throughout our body.
